JC Koster, MS Remedi, H Qiu, CG Nichols, … - Diabetes, 2003 - Am Diabetes Assoc HIV protease inhibitors (PIs) acutely and reversibly inhibit the
insulin-responsive glucose transporter Glut 4, leading to peripheral insulin
resistance and impaired glucose tolerance. Minimal modeling analysis of ... Cited by 52 - Related articles - BL Direct - All 5 versions
HJ Woerle, PR Mariuz, C Meyer, RC Reichman … - Diabetes, 2003 - Am Diabetes Assoc The mechanisms responsible for the deterioration in glucose tolerance associated
with protease inhibitor–containing regimens in HIV infection are unclear.
Insulin resistance has been implicated as a major factor, but the affected ... Cited by 95 - Related articles - BL Direct - All 9 versions
M Düfer, Y Neye, P Krippeit-Drews, G Drews - Naunyn-Schmiedeberg's archives of pharmacology, 2004 - Springer Abstract The aim of the present study was to evaluate whether HIV protease
inhibitors directly interfere with stimulus-secretion coupling in pancreatic
β-cells. Insulin secretion was determined by a radioimmunoassay (RIA), ... Cited by 14 - Related articles - BL Direct - All 5 versions
- ►endocrinology-journals.org M Schutt, J Zhou, M Meier, HH Klein - Journal of Endocrinology, 2004 - Soc Endocrinology The mechanism by which chronic treatment with HIV (human immunodeficiency
virus)-1 protease inhibitors leads to a deterioration of glucose metabolism
appears to involve insulin resistance, and may also involve impaired ... Cited by 23 - Related articles - All 4 versions
J Hertel, H Struthers, CB Horj, PW Hruz - Journal of Biological Chemistry, 2004 - ASBMB Human immunodeficiency virus (HIV) protease inhibitors (PIs) act as reversible
noncompetitive inhibitors of GLUT4 with binding affinities in the low micromolar
range and are known to contribute to alterations in glucose homeostasis ... Cited by 40 - Related articles - All 5 versions
PW Hruz, H Murata, H Qiu, M Mueckler - Diabetes, 2002 - Am Diabetes Assoc The use of HIV protease inhibitors (PIs) has been associated with several
metabolic changes, including lipodystrophy, hyperlipidemia, and insulin
resistance. The etiology of these adverse effects remains unknown. PIs have ... Cited by 75 - Related articles - BL Direct - All 4 versions
H Murata, PW Hruz, M Mueckler - Aids, 2002 - journals.lww.com Objectives: To determine the relative sensitivities of glucose transporter
isoforms to the protease inhibitor indinavir and to determine the kinetic
mechanism of indinavir- mediated Glut4 isoform inhibition. Methods: The ... Cited by 150 - Related articles - All 3 versions
M Schütt, M Meier, M Meyer, J Klein, SP Aries … - Diabetologia, 2000 - Springer Patients treated with human immunodeficiency vi- rus-1 (HIV-1) protease
inhibitors frequently develop IGT or diabetes [1]. The underlying cause seems to
be a protease inhibitor-induced insulin resistance [1]. We investigated ... Cited by 41 - Related articles - BL Direct - All 3 versions
MA Noor, T Seneviratne, FT Aweeka, JC Lo, … - Aids, 2002 - journals.lww.com From the From the Department of a Medicine, University of California, the b
Metabolism and Endocrine Sections, San Francisco Department of Veterans Affairs
Medical Center, the Department of c Pharmacology University of California, ... Cited by 215 - Related articles - BL Direct - All 8 versions
GA Lee, MN Rao, C Grunfeld - Current HIV/AIDS Reports, 1996 - Springer Introduction Since the advent of highly active antiretroviral therapy (HAART)
and HIV protease inhibitor (PI) use, morbidity and mortality from HIV and its
complications have declined. However, a constellation of metabolic ... Cited by 19 - Related articles - BL Direct - All 4 versions
